Details of Disease

General Information of Disease (ID: DISJ1FYS)

• Disease Name: Kidney transplant rejection
• Disease Class: NE84: Transplant rejection
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISJ1FYS: Kidney transplant rejection
• ICD Code:
  ICD-11: ICD-11: NE84
  ICD-9: ICD-9: 996.81
  Expand ICD-11: 'NE84
  Expand ICD-10: 'T86; 'T86.1; 'T86.3; 'T86.4; 'T86.9
  Expand ICD-9: 996.81
• Disease Identifiers:
  MedGen ID: 536781
  SNOMED CT ID: 236570004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Belatacept	DMXLYQF	Approved	NA	[1]
Daclizumab	DM6OZQV	Approved	Monoclonal antibody	[2]
Methoxy polyethylene glycol-epoetin beta	DMK1LZD	Approved	NA	[3]
Tacrolimus	DMZ7XNQ	Approved	Small molecular drug	[4]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MDR-101	DMIMJNB	Phase 3	Cell therapy	[5]
Dazodalibep	DM7YII9	Phase 2	NA	[6]
MDR-102	DM3N6ME	Phase 2	Cell therapy	[7]
MDR-103	DM2T41T	Phase 2	Cell therapy	[8]
NX-001	DMYX0HY	Phase 1	NA	[9]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Triplelastat	DMBONWW	Investigative	NA	[10]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6892).
• [2] Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.
• [3] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [4] Tacrolimus FDA Label
• [5] ClinicalTrials.gov (NCT03363945) Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04046549) A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT03605654) Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT03606746) Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants. U.S. National Institutes of Health.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032729)
• [10] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.